Challenges in Head and Neck Therapy for Malignant Neoplasm. The Paradigm Changes in XXI Century
Received Date: Apr 24, 2014 / Accepted Date: Apr 26, 2014 / Published Date: May 03, 2014
The great majority (70%) of patients with head and neck cancer are diagnosed in stages III and IV. The new therapeutic paradigm is based on clinical stage, histopathological features (90% with squamous cell carcinoma), and new staging methods as PET-CT.
Considered that early stages (I and II) are diagnosed in 30% of cases, the best strategies are suported by surgery and or radiotherapy and for advanced stages, are indicated new schedules of chemotherapy plus irradiation, followed or not by salvage surgery and palliation regimens. Theses approaches led us for cross roads between choosing radical procedures or conservative managements, considering the Global Survival (GS) and the Free Disease Survival (FDS) as the Best parameter for therapeutic sucess [1,2].
1. General Director of Hospital Heliópolis, São Paulo, Brazil.
2. Radiologist of Hospital Heliópolis, São Paulo, Brazil.
3. Head of Head and Neck Department of Hospital Heliópolis, São Paulo, Brazil.
The mean age after 60 years old of head and neck cancer incidence, is mandatory in the stablishment of a new algorithm for the acceptance of The New Approach for Squamous Cell Carcinoma of the Head and Neck for the new century basing on:
The routinely use of PET-CT (Computed Tomography) before the begining of the therapy
The PET-CT (Computed Tomography with Positron Emission) is indicated previously the therapy planning, being in 30% of cases diagnosed in stages I/II and 70% for advanced stages III/IV. Based on theses facts, usually, the initial approach is conditioned for changes depending of this method, obliging the head and neck oncologist to review the historical results. For advanced stages, the chemotherapy association is followed by salvage surgery and palliation, allowing the increase of global survival of 6 to 12 months, not considering the cost augmentation of the schedule that cannot be supported by the Oncologic Health Program. Then, remains the question that is mandatory the budget revision for the oncologic program, considering the supporting of the population involved by these neoplasias.
Another question for discussion is the degree of concentration of the radiopharmaco in the central part of the neoplasia and for the peripheric cell population of the lesion, determining a new surgical margin preventing the recurrence of the tumor.
The main doubt concerns the necessity of the consideration of molecular limits for the SCC of the Head and Neck, influencing the follow up till 2 years. For theses cases, the indication of radiotherapy would be mandatory. When the irradiation, preceed the surgical indication, the salvage rescue include the initial limits of the tumor, previously of the radiotherapy [3,4].
The immunohistochemical method suggest genetic polimorphism, supporting the idea that nom neoplasic tissue are affected and must be included in the field of treatment. Beside this fact, the Micro Tissue Array (MTA) allow the clinician to suggest routinely the association of chemoirradiation to limit the systemic spread of the neoplasia for distant organs .
For head and neck cancer, 90% of cases are diagnosed through hematoxilin eosin, and only in 10% is necessary the immunohistochemical method, considering that the SCC is diagnosed through its morphologic features.
For the remaining group (glandular tumors, sarcomas and indifferentiated carcinoma), tumoral cell markers are necessery to establish the best approach, where the oncogenes expression (EGF and other products as cycleoxigenase 2) are usually recomended as prognostic factors .
Surgery and or irradiation are the usual methods for the therapy in head and neck squamous cell carcinoma for stages I, II and eventually III. For stage IV, chemotherapy is usual in association with surgery and and radiotherapy.
In spite of this algorithm, the successful of these procedures are limited, and in 60% of theses cases, it is necessary new approaches for the rescue of these patients. These neoplasias usually course with failure results, and for these phases, we introduce new protocols of palliation where the patients are submitted to new drugs that allow a end of life without pain, and generation of quality of life [6-9].
Future of Head and Neck Therapy
Considered that the diagnosis of head and neck cancer in early stages are unusual, for advanced cases, the majority of HNSCC are treated with therapeutic association to treat the elderly patients with comorbidities and the influence in global survival. The main question is concerned “how to handlle with these groups of patients where is necessary the establishment of individual treatment considering the history and the real necessity of each one”.
These neoplasias usually course with failure, and for these phases, we introduce new protocols of palliation, where the patients are submitted to new drugs that allow end of life without pain.
- Gani C, Eckert F, MÃ¼ller AC, Mauz PS, Thiericke J, et al. (2013) Cervical squamous cell lymph node metastases from an unknown primary site: survival and patterns of recurrence after radiotherapy. Clin Med Insights Oncol 7: 173-180.
- Amar A, Rapoport A, Curioni AO, Dedivitis RA, Cernea CR, et al. (2013) Prognostic Value of regional metastasis in squamous cell carcinoma of the tongue and mouth. Braz J Otorhinolaryngol 79:734-737.
- Chedid HM, Amar A, Rapoport A, Curioni OA, Souza RP, et al. (2013)AnÃ¡lise do PET-CT no estadiamento do carcinoma epidermÃ³ide de cabeÃ§a e PescoÃ§o. Rev Bras Cir Cab Pesc 42:153-156.
- Curioni AO, Carvalho MB, Dedivitis RA, Rapoport A, Gattas GJF (2013) The Influence of gene polymorphisms on tobacco and alcohol-induced oral cancer risk. J Cancer Ther 4:978-988.
- CalyDde N, Rapoport A, Curioni OA, Dedivitis RA, Cernea CR, et al. (2013) Value of immunohistochemistry in the diagnosis of malignant cervical lymph nodes. Braz J Otorhinolaryngol 79: 625-628.
- McLarnon C, Kulloo P, Mehanna H, Kelly C, Paleri V (2010) Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer. Expert Rev Anticancer Ther 10: 345-352.
- Sciubba JJ (2009) End of life considerations in the head and neck cancer patient. Oral Oncol 45: 431-434.
- Shuman AG, Fins JJ, Prince ME (2012) Improving end-of-life care for head and neck cancer patients. Expert Rev Anticancer Ther 12: 335-343.
- Shuman AG , Yang Y, Taylor JM, Prince ME (2011) End-of-life care among head and neck cancer patients. Otolaryngol Head Neck Surg 144: 733-739.
Citation: Rapoport A, Souza RPd, Curioni OA (2014) Challenges in Head and Neck Therapy for Malignant Neoplasm. The Paradigm Changes in XXI Century. Otolaryngology 4:e109. Doi: 10.4172/2161-119X.1000e109
Copyright: © 2014 Rapoport A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 12045
- [From(publication date): 8-2014 - Sep 24, 2020]
- Breakdown by view type
- HTML page views: 8205
- PDF downloads: 3840